Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Cost of Revenue (2016 - 2025)

Standard Biotools (LAB) has disclosed Cost of Revenue for 16 consecutive years, with $10.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 1.09% to $10.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $87.8 million, a 84.79% increase, with the full-year FY2024 number at $90.2 million, up 61.33% from a year prior.
  • Cost of Revenue was $10.1 million for Q3 2025 at Standard Biotools, up from -$747000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $57.5 million in Q4 2024 to a low of -$18.9 million in Q3 2021.
  • A 5-year average of $15.3 million and a median of $14.1 million in 2023 define the central range for Cost of Revenue.
  • Biggest YoY gain for Cost of Revenue was 1702.99% in 2021; the steepest drop was 1169.98% in 2021.
  • Standard Biotools' Cost of Revenue stood at $47.8 million in 2021, then tumbled by 36.22% to $30.5 million in 2022, then plummeted by 51.41% to $14.8 million in 2023, then skyrocketed by 287.47% to $57.5 million in 2024, then plummeted by 82.48% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cost of Revenue are $10.1 million (Q3 2025), -$747000.0 (Q2 2025), and $21.1 million (Q1 2025).